Cargando…

The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis

BACKGROUND: Osteosarcoma, a primary malignant bone tumor derived from mesenchymal tissue, is the most common type of pleomorphic tumor that occurs in children and adolescents. The aim of this study was to compare the efficacy and safety of high-dose methotrexate (M), doxorubicin (D), cisplatin (C),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Bin, Zhang, Yan, Li, Rongzhen, Li, Jiazhen, Lu, Xinchang, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7020590/ https://www.ncbi.nlm.nih.gov/pubmed/32054494 http://dx.doi.org/10.1186/s13018-020-1576-0

Ejemplares similares

Efficacy of ifosfamide, dacarbazine, doxorubicin and cisplatin in human sarcoma xenografts.
por: Budach, W., et al.
Publicado: (1994)

Assessing the Percent of Necrosis after Neoadjuvant Chemotherapy with 24hr Infusional Cisplatin/3 Days Doxorubicin Intermittent with Ifosfamide-Doxorubicin for Osteosarcoma
por: Samimi, Mozhgan Aalam, et al.
Publicado: (2014)

Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma
por: Michelagnoli, M P, et al.
Publicado: (1999)

Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
por: Katz, Daniela, et al.
Publicado: (2012)

Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
por: Chung, Doo Yong, et al.
Publicado: (2021)

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma
por: Requilé, Annelies, et al.
Publicado: (2017)

Efficacy of methotrexate, doxorubicin, and cisplatin for osteosarcoma: Study protocol for a systematic review of randomized controlled trial
por: Tang, Qing-xi, et al.
Publicado: (2019)

Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment
por: Xie, Duoli, et al.
Publicado: (2022)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Self‐Stabilized Hyaluronate Nanogel for Intracellular Codelivery of Doxorubicin and Cisplatin to Osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2018)

Effect assessment of methotrexate in combination with other chemotherapeutic agents for osteosarcoma in children: A protocol for systematic review and meta-analysis
por: Yan, Jun-Ping, et al.
Publicado: (2021)

Single‐Center Experience with Ifosfamide Monotherapy as Second‐Line Treatment of Recurrent/Metastatic Osteosarcoma
por: Verschoor, Arie Jan, et al.
Publicado: (2019)

Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis
por: Fan, Xiao-Liang, et al.
Publicado: (2015)

Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin
por: Qu, Yang, et al.
Publicado: (2022)

Systemic complications of the bidirectional intraoperative chemotherapy with intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin plus doxorubicin
por: Hakeam, Hakeam, et al.
Publicado: (2019)

Clinical therapeutic effects of combined methotrexate and other chemotherapeutic agents in treating children and young patients with osteosarcoma: A protocol for systematic review and meta-analysis
por: Peng, Cheng, et al.
Publicado: (2021)

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)

High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
por: Palmerini, Emanuela, et al.
Publicado: (2020)

Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin‐Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin
por: Fox, Elizabeth, et al.
Publicado: (2018)

Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy
por: Wu, Haixiao, et al.
Publicado: (2022)

Identification of genes associated with methotrexate resistance in methotrexate-resistant osteosarcoma cell lines
por: Yang, Xiao-rong, et al.
Publicado: (2015)

Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin
por: Hou, Kai, et al.
Publicado: (2021)

Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients
por: Zhang, Wei, et al.
Publicado: (2016)

Genetic and cellular sensitivity of Caenorhabditis elegans to the chemotherapeutic agent cisplatin
por: García-Rodríguez, Francisco Javier, et al.
Publicado: (2018)

Sequential Dose-Dense Doxorubicin and Ifosfamide in Advanced Soft-Tissue Sarcoma Patients in an Out-Patient-Basis Schedule
por: Almeida, G. F. G., et al.
Publicado: (2011)

Developing a 5-Gene Signature Related to Pyroptosis for Osteosarcoma Patients
por: Li, Zhe, et al.
Publicado: (2022)

Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure
por: Savani, Malvi, et al.
Publicado: (2019)

Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study
por: Tian, Zhichao, et al.
Publicado: (2021)

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
por: Leyvraz, S, et al.
Publicado: (2006)

Neoadjuvant and adjuvant chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients
por: URAKAWA, HIROSHI, et al.
Publicado: (2014)

Effective Treatment of a Malignant Breast Phyllodes Tumor with Doxorubicin-Ifosfamide Therapy
por: Yamamoto, Shinya, et al.
Publicado: (2019)

Doxorubicin and ifosfamide for recurrent renal synovial sarcoma: The first case report in Indonesia
por: Fitra, Ahmad Fathira, et al.
Publicado: (2022)

Rapidly Progressive Lung Sarcomatoid Carcinoma Managed with Doxorubicin Plus Ifosfamide and Pemetrexed
por: Paredes Mogica, Jan Alberto, et al.
Publicado: (2021)

Mechanisms of methotrexate resistance in osteosarcoma cell lines and strategies for overcoming this resistance
por: WANG, JIANJUN, et al.
Publicado: (2015)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Ifosfamide-loaded lipid-core-nanocapsules to increase the anticancer efficacy in MG63 osteosarcoma cells
por: Wang, Sheng-Qun, et al.
Publicado: (2018)

Safety and efficacy of high‐dose methotrexate for osteosarcoma in adolescents compared with young adults
por: Wippel, Brittany, et al.
Publicado: (2018)

Construction of a novel mRNAsi-related risk model for predicting prognosis and immunotherapy response in osteosarcoma
por: Li, Zhe, et al.
Publicado: (2023)

Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation
por: Yu, Dapeng, et al.
Publicado: (2019)

The chemotherapeutic drug methotrexate selects for antibiotic resistance
por: Guðmundsdóttir, Jónína S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_973c1mremnsujiu2kf4gl9vgur